Idioma:

Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations

Mao-Draayer, Yang ; Thiel, Sandra ; Mills, Elizabeth A ; Chitnis, Tanuja ; Fabian, Michelle ; Katz Sand, Ilana ; Leite, M Isabel ; Jarius, Sven ; Hellwig, Kerstin

Nature reviews. Neurology, 2020-03, Vol.16 (3), p.154-170 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations
Autor: Mao-Draayer, Yang ; Thiel, Sandra ; Mills, Elizabeth A ; Chitnis, Tanuja ; Fabian, Michelle ; Katz Sand, Ilana ; Leite, M Isabel ; Jarius, Sven ; Hellwig, Kerstin
Assuntos: Abnormalities, Drug-Induced ; Abortion, Spontaneous - chemically induced ; Adult ; Autoimmune diseases ; Autoimmunity ; Care and treatment ; Complications and side effects ; Development and progression ; Female ; Health aspects ; Humans ; Immune response ; Immunologic Factors - adverse effects ; Neuromyelitis optica ; Neuromyelitis Optica - drug therapy ; Neuromyelitis Optica - immunology ; Obstetric Labor Complications - chemically induced ; Patient outcomes ; Pre-Eclampsia - chemically induced ; Pregnancy ; Pregnancy, Complications of ; Risk factors
É parte de: Nature reviews. Neurology, 2020-03, Vol.16 (3), p.154-170
Descrição: Neuromyelitis optica spectrum disorders (NMOSD) are a type of neurological autoimmune disease characterized by attacks of CNS inflammation that are often severe and predominantly affect the spinal cord and optic nerve. The majority of individuals with NMOSD are women, many of whom are of childbearing age. Although NMOSD are rare, several small retrospective studies and case reports have indicated that pregnancy can worsen disease activity and might contribute to disease onset. NMOSD disease activity seems to negatively affect pregnancy outcomes. Moreover, some of the current NMOSD treatments are known to pose risks to the developing fetus and only limited safety data are available for others. Here, we review published studies regarding the relationship between pregnancy outcomes and NMOSD disease activity. We also assess the risks associated with using disease-modifying therapies for NMOSD during the course of pregnancy and breastfeeding. On the basis of the available evidence, we offer recommendations regarding the use of these therapies in the course of pregnancy planning in individuals with NMOSD.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations

Mao-Draayer, Yang ; Thiel, Sandra ; Mills, Elizabeth A ; Chitnis, Tanuja ; Fabian, Michelle ; Katz Sand, Ilana ; Leite, M Isabel ; Jarius, Sven ; Hellwig, Kerstin

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.